Skip to main content
    N

    Niagen Bioscience, Inc. (NAGE)

    Official site

    CONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ

    $2.07
    -0.03 (-1.66%)

    Market Cap: $166.56M

    Last updated: Nov 06, 2026 at 4:36 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(23/36)
    Avg Surprise
    +12.13%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    Revenue Consensus
    $37M
    Range$34M - $39M
    4 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.02$-0.02 - $-0.02--1--
    Sep 26
    Reported Nov 4
    		$-0.01$-0.01-+0.00%Beat1
    0
    1
    30d
    		-120.0%
    Jun 26
    Reported Aug 4
    		$0.01$0.01$0.01 - $0.01+0.00%Beat1
    No revisions (30d)
    		-75.0%
    Mar 26
    Reported May 6
    		$0.02N/A--66.67%Miss1
    1
    0
    30d
    		-60.0%
    Dec 25
    Reported Mar 4
    		$0.03$0.02$0.02 - $0.03+25.45%Beat3
    1
    0
    30d
    		-69.3%
    Sep 25
    Reported Nov 4
    		$0.05$0.02$0.01 - $0.04+150.00%Beat3
    No revisions (30d)
    		+150.0%
    Jun 25
    Reported Aug 6
    		$0.04$0.01$-0.01 - $0.03+300.00%Beat3
    0
    1
    30d
    		+154.8%
    Mar 25
    Reported May 7
    		$0.05$0.02-+150.00%Beat--+600.0%
    Dec 24
    Reported Mar 4
    		$0.09$0.02-+350.00%Beat--+5900.0%
    Sep 24
    Reported Oct 31
    		$0.02$0.01-+100.00%Beat--+300.0%
    Jun 24
    Reported Aug 7
    		$0.02$-0.01-+257.00%Beat--+152.3%
    Mar 24
    Reported May 8
    		$-0.01$-0.01-+0.00%Beat--+66.7%
    Dec 23
    Reported Mar 6
    		$0.00N/A-+106.67%Beat--+107.5%

    Key Metrics

    Valuation
    P/E Ratio43.49EV/EBITDA8.88x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin12.40%Operating Margin2.35%
    ROE21.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio5.93xQuick Ratio4.71x
    Trading Statistics
    Beta2.08Avg Volume545.65K
    52-Week High$7.2852-Week Low$2.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.38
    SMA 20$2.45
    SMA 50$2.76
    SMA 200$3.82
    EMA 10$2.34
    EMA 20$2.45
    EMA 50$2.71
    EMA 200$3.99

    MACD

    Line: -0.15Signal: -0.13Hist: -0.02

    ADX

    ADX: 42.6+DI: 15.1-DI: 40.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$2.58

    Bollinger Bands

    Upper Band$2.74
    Lower Band$2.16
    %B Position2346%(Upper)
    Band Width-0.16

    RSI (14-Day)

    Oversold
    29.9

    Momentum Oscillators

    Stoch %K30.5
    Stoch %D35.0
    Williams %R-93.7
    ROC (10d)-14.8%
    Momentum-0.36
    CCI (20d)-271.7
    MFI (14d)44.8

    Volatility Measures

    ATR (14d)$0.13(6.2%)
    StdDev (20d)0.14
    Hist Vol73.7%(High)

    Volume Flow

    VWAP$2.07
    OBV-6.0M
    AD Line-32.7M
    CMF (20d)-0.060

    Volume Metrics

    Avg Vol (20d)555.1K
    Vol Ratio1.1x
    VWMA (20d)$2.42

    Pivot Points

    R3$2.57
    R2$2.46
    R1$2.28
    Pivot Point$2.17
    S1$1.99
    S2$1.88
    S3$1.70

    Advanced Oscillators

    TSI-32.25
    Ultimate Osc35.4
    KST-150.42

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$27.19M$29.79M$31.47M$33.84M$33.99M$31.12M$30.48M$29.13M$25.58M$22.74M$22.15M$21.20M
    Cost of Revenue$10.09M$10.47M$11.50M$12.13M$12.06M$10.89M$11.15M$10.93M$9.34M$9.05M$8.70M$8.26M
    Gross Profit$17.11M$19.31M$19.98M$21.70M$21.93M$20.23M$19.33M$18.20M$16.24M$13.69M$13.46M$12.94M
    Operating Expenses$18.69M$18.61M$18.40M$17.62M$17.69M$17.04M$14.56M$11.09M$14.64M$13.95M$14.19M$13.11M
    R&D$1.80M$1.51M$1.48M$1.71M$1.79M$1.57M$1.26M$1.31M$1.29M$1.32M$2.10M$1.16M
    SG&A$8.18M$6.97M$7.24M$7.48M$7.13M$7.27M$5.18M$1.05M$6.30M$5.66M$5.35M$5.43M
    Operating Income$-1,587,000$700,000$1.58M$4.09M$4.24M$3.19M$4.77M$7.11M$1.60M$-256,000$-731,000$-168,000
    Interest Income$414,000$372,000$375,000$552,000$564,000$552,000$459,000$373,000$276,000$241,000$239,000$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-1,173,000$1.07M$6.74M$4.42M$4.80M$3.74M$5.23M$7.48M$1.88M$-15,000$-492,000$114,000
    Income Tax Expense$0$106,000$417,000$292,000$222,000$128,000$168,000$305,000$0$0$0$0
    Net Income$-1,173,000$963,000$6.32M$4.13M$4.58M$3.61M$5.06M$7.18M$1.88M$-15,000$-492,000$114,000
    EBITDA$-1,297,000$988,000$6.65M$4.29M$4.43M$3.38M$4.97M$7.30M$1.80M$-49,000$-515,000$-472,000
    EBIT$-1,587,000$697,000$6.36M$4.09M$4.24M$3.19M$4.77M$7.11M$1.60M$-256,000$-731,000$-168,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NAGE

    NAGE Valuation and Fair Value

    P/E
    43.5x
    Forward P/E
    18.0x
    EV/EBITDA
    8.9x
    P/B
    2.0x
    See GNG's fair value

    NAGE Profitability: Margins, ROIC and FCF

    Gross margin
    63.9%
    Operating margin
    2.4%
    Net margin
    12.4%
    ROE
    21.8%
    FCF margin
    3.9%

    NAGE Competitors

    CompanyTicker
    Zentalis Pharmaceuticals LlcZNTL
    OPTIMIZERx CorpOPRX
    PepGen LtdPEPG
    EDAP TMS SAEDAP
    Whitehawk Therapeutics, Inc.WHWK
    AN2 Therapeutics IncANTX
    Invivyd Inc.IVVD
    Oramed Pharmaceuticals IncORMP

    Sector: Healthcare

    NAGE Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    0
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    NAGE Bull Case vs Bear Case

    Bull case

    • 100.0% of NAGE's analyst ratings are Buy or Strong Buy.

    Bear case

    • NAGE trades at 43.5x trailing earnings.
    • NAGE's quarterly revenue changed -4.3% year over year.

    NAGE Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    113.6%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.02

    NAGE Earnings Date

    NAGE reports Mar 2, 2027, after the close. The date is estimated.

    NAGE Earnings Call

    The latest NAGE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    NAGE ETF Holders

    GNG tracks 9 ETFs that hold NAGE. The largest weights:

    1. VictoryShares Small Cap Free Cash Flow ETF (SFLO), 0.08% of the fund
    2. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    3. Vanguard Consumer Staples Index Fund ETF Shares (VDC), 0.02% of the fund
    4. Vanguard Extended Market Index Fund ETF Shares (VXF), 0.02% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
    Open the ETF Stock Exposure tool for NAGE

    Frequently Asked Questions About NAGE

    When does NAGE report earnings?

    Niagen Bioscience, Inc. (NAGE) is expected to report earnings on Mar 2, 2027.

    Does NAGE pay dividends?

    Niagen Bioscience, Inc. (NAGE) does not currently pay a regular dividend.

    What is NAGE's P/E ratio?

    Niagen Bioscience, Inc. has a price-to-earnings (P/E) ratio of 43.49.

    What is NAGE's market cap?

    Niagen Bioscience, Inc. (NAGE) has a market capitalization of $166.56M with a current stock price of $2.07.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In